Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction

被引:12
作者
Karmpaliotis, D
Turakhia, MP
Kirtane, A
Murphy, SA
Kosmidou, I
Morrow, DA
Giugliano, RP
Cannon, CP
Antman, EM
Braunwald, E
Gibson, CM
机构
[1] Beth Israel Deaconess Med Ctr, TIMI Study Grp, Dept Med, Brigham & Womens Hosp, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
关键词
D O I
10.1016/j.amjcard.2004.07.075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the setting of ST-segment elevation myocardial infarction (STEMI), the Thrombolysis In Myocardial Infarction (TIMI) risk score (TRS) and indexes of epicardial and myocardial perfusion are associated with mortality. The association between TRS at presentation and angio-graphic indexes of epicardial and myocardial perfusion after reperfusion therapy has not been investigated. We hypothesized that TRS, TIMI flow grade (TFG), and TIMI myocardial perfusion grade (TMPG) would provide independent prognostic information and that angiographic indexes of poor flow and perfusion would be associated with a higher TRS. TRS and angiographic data were evaluated in 3,801 patients from the TIMI 4, 10A, 10B, 14, 20, 23, and 24 trials. Within each TRS stratum (TRS 0 to 2, 3 to 4, greater than or equal to5), 30-day mortality increased stepwise among-patients with impaired TFG at 60 minutes after fibrinolytic administration. In a multivariate model adjusting for the IRS strata, impaired TMPG (0/1) was independently associated with higher mortality (odds ratio 2.28, p = 0.018). In a multivariate model adjusting for the TFG and infarct location, the likelihood of impaired TMPG (0/1) was greater among intermediate-risk (TRS 3 to 4) and high-risk (TRS 5) patients than among low-risk (TRS 0 to 2) patients (odds ratio 1.43, p = 0.019 and 1.50, p = 0.055, respectively). Thus, impaired epicardial flow and myocardial perfusion are independently associated with increased 30-day mortality among patients identified by TRS as high risk, although there is no synergism between either TFG or TMPG and TRS. High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders. (C)2004 by Excerpta Medica, Inc.
引用
收藏
页码:1113 / 1117
页数:5
相关论文
共 20 条
[1]   Thrombolysis in Myocardial Infarction frame count in saphenous vein grafts [J].
Al-Mousa, EN ;
Dodge, JT ;
Rizzo, M ;
McLean, C ;
Ryan, K ;
Moynihan, J ;
Kelley, M ;
Marble, SJ ;
Goel, M ;
Daley, WL ;
Gibson, CM .
AMERICAN HEART JOURNAL, 1998, 135 (02) :323-328
[2]   Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].
Antman, EM ;
Giugliano, RP ;
Gibson, CM ;
McCabe, CH ;
Coussement, P ;
Kleiman, NS ;
Vahanian, A ;
Adgey, AAJ ;
Menown, I ;
Rupprecht, HJ ;
Van der Wieken, R ;
Ducas, J ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1999, 99 (21) :2720-2732
[3]   Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction - Results of the ENTIRE-thrombolysis in myocardial infarction (TIMI) 23 trial [J].
Antman, EM ;
Louwerenburg, HW ;
Baars, HF ;
Wesdorp, JCL ;
Hamer, B ;
Bassand, JP ;
Bigonzi, F ;
Pisapia, G ;
Gibson, CM ;
Heidbuchel, H ;
Braunwald, E ;
Van de Werf, F .
CIRCULATION, 2002, 105 (14) :1642-1649
[4]   TNK tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction - Results of the TIMI 10B trial [J].
Cannon, CP ;
Gibson, CM ;
McCabe, CH ;
Adgey, AAJ ;
Schweiger, MJ ;
Sequeira, RF ;
Grollier, G ;
Giugliano, RP ;
Frey, M ;
Mueller, HS ;
Steingart, RM ;
Weaver, WD ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1998, 98 (25) :2805-2814
[5]   COMPARISON OF FRONT-LOADED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, ANISTREPLASE AND COMBINATION THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) 4 TRIAL [J].
CANNON, CP ;
MCCABE, CH ;
DIVER, DJ ;
HERSON, S ;
GREENE, RM ;
SHAH, PK ;
SEQUEIRA, RF ;
LEYA, F ;
KIRSHENBAUM, JM ;
MAGORIEN, RD ;
PALMERI, ST ;
DAVIS, V ;
GIBSON, CM ;
POOLE, WK ;
BRAUNWALD, E ;
PULEO, P ;
ABENDSCHEIN, D ;
LOSCALZO, J ;
CHAITMAN, BR ;
ZARET, BL ;
DANGOISSE, V ;
FLAKER, GC ;
GARRISON, TW ;
SCHWEIGER, MJ ;
MAHRER, PR ;
SHOOK, TL ;
ANDERSON, JL ;
PALISAITIS, D ;
COHN, PF ;
LARAMEE, LA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (07) :1602-1610
[6]  
Cannon CP, 1997, CIRCULATION, V95, P351
[7]   Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected thrombolysis in myocardial infarction (TIMI) frame count and stenosis severity [J].
French, JK ;
Ellis, CJ ;
Webber, BJ ;
Williams, BF ;
Amos, DJ ;
Ramanathan, K ;
Whitlock, RML ;
White, HD .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (06) :665-671
[8]   Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs [J].
Gibson, CM ;
Cannon, CP ;
Murphy, SA ;
Ryan, KA ;
Mesley, R ;
Marble, SJ ;
McCabe, CH ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 2000, 101 (02) :125-130
[9]   TIMI frame count: A quantitative method of assessing coronary artery flow [J].
Gibson, CM ;
Cannon, CP ;
Daley, WL ;
Dodge, JT ;
Alexander, B ;
Marble, SJ ;
McCabe, CH ;
Raymond, L ;
Fortin, T ;
Poole, WK ;
Braunwald, E .
CIRCULATION, 1996, 93 (05) :879-888
[10]   Relationship between TIMI frame count and clinical outcomes after thrombolytic administration [J].
Gibson, CM ;
Murphy, SA ;
Rizzo, MJ ;
Ryan, KA ;
Marble, SJ ;
McCabe, CH ;
Cannon, CP ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1999, 99 (15) :1945-1950